Rapid response halts diphtheria outbreak among refugees in Mauritania
In a densely populated refugee setting with limited health infrastructure, even a handful of cases could quickly spiral into crisis. Mauritania's Ministry of Health, supported by the World Health Organization (WHO) and humanitarian partners, moved fast. Within 72 hours of laboratory confirmation, a full outbreak response was under way.
Between July and September 2024, at least ten cases of diphtheria, including two deaths, were recorded in the Mberra camp. Of these cases, eight were in children, six of whom were under five years of age, all of whom were unvaccinated. In response, more than a thousand people were vaccinated, including nearly 70 health professionals.
In addition, over two tonnes of emergency supplies were delivered to the camp, including antitoxins, antibiotics, personal protective equipment and disinfectants. WHO deployed technical experts to support case investigation, contact tracing and coordination with national and local teams. Community health workers were rapidly trained to identify symptoms, isolate cases and provide prevention education to families.
'Before the training, many of us had never seen a case of diphtheria,' says Fatou, a community health volunteer. 'Now we know what to look for, and how to respond.'
A targeted risk communication and community engagement campaign used megaphones, posters and local radio in multiple languages to build trust, educate communities and ensure early reporting of symptoms.
Thanks to this rapid, coordinated approach, the outbreak was contained within weeks. No deaths were reported, and all cases remained confined to the initial cluster.
"This was a textbook example of what rapid mobilization and partnership can achieve," says Dr Charlotte Faty Ndiaye, WHO Representative in Mauritania. "In a fragile setting like Mberra, early action saved lives."
The experience underlined the importance of preparedness, coordination and community engagement in humanitarian contexts. WHO and partners, working hand-in-hand with Mauritania's Ministry of Health, turned a looming health emergency into an example of public health equity in action.
Awareness-raising campaigns were carried out in communities and among humanitarian personnel to encourage vaccination, with a particular focus on diphtheria prevention. Between July 2024 to May 2025, more than 2300 newly arrived individuals at Mberra camp were vaccinated.
Distributed by APO Group on behalf of World Health Organization (WHO) - Mauritania.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
5 hours ago
- Zawya
Africa Must Reduce Reliance on Imported Medicines, World Health Organization (WHO) Urges at Regional Good Manufacturing Practices (GMP) Training Workshop
Africa must prioritize pharmaceutical self-reliance by boosting local medicine production rooted in global quality standards, said Dr Owen Laws Kaluwa, WHO Representative to Ethiopia, in a keynote address delivered at a regional training workshop on Good Manufacturing Practices (GMP) held in Addis Ababa. The two-day hands-on workshop, held from 22–23 July 2025, brought together 26 participants from National Regulatory Authorities (NRAs) and pharmaceutical manufacturers across seven East African Community (EAC) member states. It was jointly organized by the Local Production and Assistance Unit in WHO Headquarters, the WHO Regional Office for Africa (AFRO), and the WHO Country Office in Ethiopia, with financial support from The Global Fund to Fight AIDS, Tuberculosis and Malaria. Designed to strengthen technical capacities in GMP implementation, the training offered a mix of instructional content and case-based learning. Core topics included Quality Management Systems, Quality Risk Management, Corrective and Preventive Actions (CAPA), data integrity, validation practices, and management of critical utility systems such as water and HVAC. The approach strengthened practical skills in complying with current WHO GMP standards and fostered active collaboration between regulatory bodies and industry professionals, enhancing mutual understanding and shared responsibility for quality-assured pharmaceutical production. Dr Jicui Dong, Unit Head of the WHO Local Production and Assistance Unit, remarked 'Compliance with current GMP standards needs both theoretical knowledge and practical skills. It is encouraging to see the commitment of pharmaceutical manufacturers within this region to invest in workforce development and ensure local production of quality pharmaceuticals.' Opening the workshop, Mr Dejene Daba, Head of the Medicine Manufacturers Inspection and Enforcement Desk at the Ethiopian Food and Drug Authority (EFDA), reaffirmed the agency's commitment to supporting manufacturers and attaining WHO Maturity Level 3 regulatory status—a benchmark for robust regulatory systems. Dr Kaluwa underscored that reliance on imported medicines continues to pose significant health security risks for African countries, particularly in times of global supply chain disruptions. 'Enhancing local pharmaceutical production is not only a strategic health priority but also an economic and political imperative,' he said. The workshop represents a concrete step toward building regional capabilities to meet international manufacturing standards, aligning with broader continental goals such as the African Union and Africa CDC. Distributed by APO Group on behalf of World Health Organization (WHO) - Ethiopia.
Zawya
5 hours ago
- Zawya
Mpox in Malawi: A Community Effort That Proved It Can Be Beaten
Declared a Public Health Emergency of International Concern on 14 August 2024, mpox remains a health challenge across several African countries, including Malawi. The country confirmed its first mpox case on 16 April 2025, followed by an official outbreak declaration from the Ministry of Health the next day. As of 11 July 2025, the Public Health Institute of Malawi had recorded 59 confirmed cases, primarily in Lilongwe and Mangochi, with a few isolated cases in other districts. On 19 April 2025, Mangochi District registered its first suspected mpox case, a 2-year-old boy from Ntiyala Village, Traditional Authority Mponda. The child, who had no travel history or known contact with any confirmed case, was brought to the Koche Community OPD Clinic with a rash, fever, and headache. Walinase Mughogho, a Health Surveillance Assistant (HSA) at the clinic, recalls: 'The child came in with his mother like any other patient. After assessment by the clinician, mpox was suspected. We were called in to review the case. The child was isolated, and a sample was sent to Mangochi District Hospital, which later confirmed the case as mpox. We returned to the community to inform them and began contact tracing among children who had interacted with him. Some presented similar symptoms, and we sent their samples to the district hospital as well. The child was treated at home due to the mild nature of the case and the lack of a formal isolation center.' With no dedicated isolation facility, managing the case within the community posed a challenge. The only way to stop transmission was to involve the community directly. Mughogho explains: 'We had to empower the community. People were advised to stop sharing clothes, bathing in streams, crowding, and were encouraged to improve hygiene, especially around food and handwashing. Everyone had a role to play.' It was a critical moment for Ntiyala Village. Chilapula Simba, a member of the Village Development Committee and community policing group, says existing local structures were key. 'Once we confirmed there was a case, we held an emergency meeting with village leaders and HSAs. Together, we conducted a door-to-door mpox awareness campaign. We educated people on the disease, how it spreads, how to prevent it, and most importantly, we emphasized not to discriminate against the affected family.' Thanks to these efforts, the family was supported, not stigmatized, and most importantly, no new cases emerged in the village. 'As of today, this remains the only case in our community. That's a huge success, and it's all because we worked together,' Simba said. Visits from the World Health Organization and other partners followed. 'We were proud to share our experience,' said Mughogho. 'It showed that mpox is real and dangerous, but when managed correctly and with collective action, it can be contained and cured.' She emphasized the importance of collaboration: 'The turning point was our ability to work together, HSAs, the Koche Clinic, Mangochi District Hospital, and the community members. But we also faced challenges in spreading information widely. We needed more posters, access to community radio, and drama performances to reach everyone. Mpox can be defeated if we all take part.' According to Stanley Rashid, Mangochi District's Integrated Disease Surveillance and Response (IDSR) officer, the district was quick to act: 'Once Koche Clinic reported the suspected case, we convened an emergency meeting and activated the emergency response management system. Each pillar, surveillance, case management, health promotion, was assigned clear responsibilities. Surveillance teams launched active contact tracing, while case management ensured the child was monitored and cared for at home. Our health promotion team engaged Liranguka Community Radio to spread messages and interact with listeners who asked questions live.' Since the initial outbreak, Mangochi has focused on training health workers in mpox surveillance and case management. The district also conducted an after-action review to identify gaps and strengthen its preparedness and response strategy. As of now, Mangochi has reported three confirmed cases, and no mpox-related deaths across Malawi. The experience in Mangochi shows that when communities are informed, united, and supported, mpox can be stopped in its tracks. It is curable, and with the right response, preventable. 'This experience has taught us that it takes all of us, health workers, families, community leaders, and local structures, to stop the spread,' said Mughogho. 'And when we do, we win together.' Distributed by APO Group on behalf of World Health Organization (WHO) - Malawi.
Zawya
5 hours ago
- Zawya
Egypt: Capital Med plans EGX listing to raise up to $41mln in Q3
Arab Finance: Capital Med, the medical city project in Badr City, is preparing to list a stake on the Egyptian Exchange (EGX) before the end of the third quarter (Q3) of 2025, aiming to raise as much as EGP 2 billion, unnamed sources told Al Borsa News. Proceeds from the planned listing will be used to help finance the second phase of the medical complex, which is expected to cost between EGP 3 billion and EGP 5 billion. Al Ahly Pharos has been tapped to manage and promote the offering. The company announced in February that it would debut on the EGX through a direct listing in the first half (H1) of 2025, followed by a capital increase to support construction of the new phase of the project. © 2025 All Rights Reserved Arab Finance For Information Technology Provided by SyndiGate Media Inc. (
